ADARx Pharmaceuticals - About the company
ADARx Pharmaceuticals is a series C company based in San Diego (United States), founded in 2019 by Zhen Li. It operates as a Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts. ADARx Pharmaceuticals has raised $353M in funding from investors like Orbimed, Venrock and BlackRock. The company has 61 active competitors, including 20 funded and 14 that have exited. Its top competitors include companies like Senti Biosciences, CRISPR Therapeutics and 64x Bio.
Company Details
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts. The company has genetic therapeutics that precisely target RNA transcripts to enable the production of desired proteins. It helps in the nucleotide sequence specified in the genomic template that is modified to produce a different nucleotide sequence in the transcript.
- Website
- www.adarx.com/
- Email ID
- *****@adarx.com
- Registered Address
- San Diego, California
Key Metrics
Founded Year
2019
Location
San Diego, United States
Stage
Series C
Total Funding
$353M in 7 rounds
Latest Funding Round
Ranked
5th among 61 active competitors
Employee Count
95 as on May 31, 2026
Similar Companies
Legal entities associated with ADARx Pharmaceuticals
ADARx Pharmaceuticals is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ADARX PHARMACEUTICALS INC CIN: 844145188 , United States, Active | - | 67 (As on Dec 31, 2024) | - |
Sign up to download ADARx Pharmaceuticals' company profile
ADARx Pharmaceuticals's funding and investors
ADARx Pharmaceuticals has raised a total funding of $353M over 7 rounds. Its first funding round was on Jan 24, 2020. Its latest funding round was a Series C round on Aug 02, 2023 for $*****. 16 investors participated in its latest round. ADARx Pharmaceuticals has 19 institutional investors.
Here is the list of recent funding rounds of ADARx Pharmaceuticals:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Aug 02, 2023 | 3039427 | Series C | 4589935 | 1939591 | 8026298 | 1061429 |
Jan 20, 2023 | 7816608 | Series C | 5167603 | 3951873 | 2362676 | |
Jul 30, 2021 | 5737764 | Series C | 7490312 | 3599894 |
Access funding benchmarks and valuations. Sign up today!View details of ADARx Pharmaceuticals's funding rounds and investors
ADARx Pharmaceuticals' founders and board of directors
Founder? Claim ProfileHere are the details of ADARx Pharmaceuticals' key team members:
- Zhen Li: Co-Founder & CEO of ADARx Pharmaceuticals. Contact Info: 1 email address
View details of ADARx Pharmaceuticals's Founder profiles and Board Members
ADARx Pharmaceuticals' employee count trend
ADARx Pharmaceuticals has 95 employees as of May 26. Here is ADARx Pharmaceuticals's employee count trend over the years:
Uncover ADARx Pharmaceuticals' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ADARx Pharmaceuticals's Competitors and alternates
Top competitors of ADARx Pharmaceuticals include Senti Biosciences, CRISPR Therapeutics and 64x Bio. Here is the list of Top 10 competitors of ADARx Pharmaceuticals, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Senti Biosciences 2016, San Francisco (United States), Public | Developer of cell-based therapies for cancer treatment | $158M | 72/100 | |
2nd | CRISPR Therapeutics 2013, Basel (Switzerland), Public | Developer of solutions for treating human genetic diseases by using genome editing technology | $127M | 63/100 | |
3rd |  64x Bio 2017, San Francisco (United States), Series A | Developer of cell lines and production technologies for advanced therapies | $59.6M | 61/100 | |
4th | Poseida Therapeutics 2015, San Diego (United States), Acquired | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 60/100 | |
5th |  ADARx Pharmaceuticals 2019, San Diego (United States), Series C | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts | $353M | 58/100 | |
6th |  Logomix 2019, San Carlos (United States), Series A | Provider of genome engineering platform to create artificial cells | $22.6M | 57/100 | |
7th |  OXGENE 2011, Oxford (United Kingdom), Acquired | Provider of a platform for mammalian cell engineering | $28.1M | 57/100 | |
8th | Bota 2019, Lafayette (United States), Series B | Developer of AI-based platform for enzyme and strain engineering | $100M | 57/100 | |
9th | Genprex 2009, Austin (United States), Public | Developer of therapeutics to treat cancer at molecular level | $3.11M | 56/100 | |
10th | Aldevron 1998, Fargo (United States), Acquired | Manufacturing plasmid DNA, RNA, proteins, and enzymes for genomic medicine | - | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ADARx Pharmaceuticals's competitors? Click here to see the top ones
ADARx Pharmaceuticals's Investments and acquisitions
ADARx Pharmaceuticals has made no investments or acquisitions yet.
Reports related to ADARx Pharmaceuticals
Here is the latest report on ADARx Pharmaceuticals's sector:
News related to ADARx Pharmaceuticals
Filter this listMedia has covered ADARx Pharmaceuticals for a total of 3 events in the last 1 year, 2 of them have been about people movement.
•
•
ADARx Doses First Subject in Phase III Trial of ADX-324 for HAEclinicaltrialsarena.com•Oct 23, 2025•ADARx Pharmaceuticals
•
ADARx Pharmaceuticals Appoints Laura Shawver as Board ChairBenzinga•Sep 17, 2025•ADARx Pharmaceuticals
•
•
Design Therapeutics appoints Chris Storgard as CMOSeeking Alpha•Apr 17, 2025•Design Therapeutics, ADARx Pharmaceuticals
•
•
•
Fresh off massive fundraising, ADARx preps 3rd clinical program and mulls IPOFierce Biotech•Oct 03, 2023•ADARx Pharmaceuticals
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ADARx Pharmaceuticals
Explore our recently published companies
- GCC Nexus - 2025 founded, Unfunded company
- FEiPU - Jing an based, 2021 founded, Unfunded company
- Shenzhen Jiale Technology - Shenzhen based, 2016 founded, Unfunded company
- 32Byte.cn - China based, 2024 founded, Unfunded company
- Goosfraba - Bucharest based, 2020 founded, Unfunded company
- HealthSignz - Hyderabad based, 2014 founded, Unfunded company
